Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 917,000 shares on October 23, 2025, marking a positive trend in investment interest [1] - Over the past five trading days, there were four days of net increases in holdings, totaling 2.7365 million shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 39.9875 million shares [1] - As of now, southbound funds hold 1.441 billion shares of Jinxin Reproductive Medicine, representing 52.26% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On October 23, 2025, total shares held reached 1.441 billion, with a change of 917,000 shares, reflecting a 0.06% increase [2] - On October 22, 2025, total shares held were 1.440 billion, with a decrease of 3.353 million shares, indicating a -0.23% change [2] - On October 21, 2025, total shares held were 1.444 billion, with an increase of 240,300 shares, showing a 0.17% change [2] - On October 20, 2025, total shares held remained at 1.441 billion, with a minimal change of 48,000 shares [2] - On October 17, 2025, total shares held were 1.441 billion, with an increase of 2.7215 million shares, reflecting a 0.19% change [2] Company Overview - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]
锦欣生殖（01951.HK）：10月23日南向资金增持91.7万股